Shah logo.png
Shah Capital nominates two highly qualified independent director candidates for Novavax
April 15, 2024 06:00 ET | Shah Capital
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price       Shah Capital which owns 6.7% of...
Final Logo-01.png
Vaccine Adjuvant Market is estimated to be US$ 2.0 billion by 2032; Rising Prevalence of Infectious Diseases to Fuel the Market Growth - By PMI
September 25, 2023 14:00 ET | PMI
Covina, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Market overview: Adjuvant is formulated as a part of vaccine to induce protection against infection in human beings. Adjuvant has become an important...
FFF Enterprises Inc.
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
September 13, 2023 13:34 ET | FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Dyadic Logo Current.jpg
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023 08:30 ET | Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Dyadic Logo Current.jpg
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
August 10, 2022 16:00 ET | Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic Logo Current.jpg
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
July 05, 2022 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic Logo Current.jpg
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET | Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
January 10, 2022 11:18 ET | The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snap, Novavax, Zillow, and Ginkgo Bioworks and Encourages Investors to Contact the Firm
January 04, 2022 21:00 ET | Bragar Eagel & Squire
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for ONTF, SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
January 03, 2022 11:27 ET | The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...